The use of aspirin for the prevention of pre-eclampsia in high-risk pregnant women was introduced by NICE in 2010 (NICE 2010,CG107). New evidence has recently been published about the risks of chronic hypertension in pregnancy and the benefit of aspirin for the prevention of pre-eclampsia. This is detailed within the relevant sections of the summarised NICE guidelines below.
Evidence for aspirin in the prevention of pre-eclampsia NICE uses two key meta-analyses as its basis for recommending 75mg aspirin for women with one high or two moderate risk factors. Cochrane reviewed 59 RCTs which had addressed the role of aspirin in reducing the risk of pre-eclampsia (Cochrane 2007; (2) CD004659). The studies included more than 37 000 women.
Aspirin offered a small reduction in the risk of pre-eclampsia compared with placebo (RR 0.83 (CI 0.77-0.89)). It also reduced preterm births. There was no difference in the risk of gestational hypertension. There were no additional adverse pregnancy events, e.g. placental abruption, haemorrhage. 2 studies followed infants to 18m of age. One showed no adverse events; the other (which was non-blinded and had high drop-out rates) showed a small increase in gross and fine motor developmental delay.
Aspirin reduced the relative risk of pre-eclampsia equally for all women, with a pooled NNT of 72. However, in terms of absolute risk, high-risk women stand to gain the most benefit, with an NNT of 19 to prevent one episode of pre-eclampsia. This is why NICE targets this group.
A follow-up study (Lancet 2007; 369:1791) looked at individual patient data, and provides the basis for the risk factors identified by NICE. It found that high-risk women potentially benefited the most, and that the benefits for moderate-risk women were more equivocal, so NICE has determined that a woman needs 2 moderate risk factors to warrant aspirin.
A more recent systematic review (Ann Intern Med 2014; 160:695) supports the use of aspirin in women at high risk of pre-eclampsia, but the absolute benefit may be small. It found a reduced risk of preterm delivery (RR 0.86, 95% CI 0.76-0.98), intrauterine growth restriction (RR 0.8, 95% CI 0.65-0.99) and pre-eclampsia (RR 0.76 95% CI 0.62 -0.95) in high-risk women taking aspirin. There was no difference in mean blood loss or risk of post-partum haemorrhage between groups.
Testing for proteinuria
When assessing for proteinuria, NICE only makes recommendations in the context of secondary care. It says:
Use an automated reagent-strip reading device OR a spot protein:creatinine ratio. If ≥1+ proteinuria, use spot PCR to quantify. PCR >30mg/mmol or 24-hour urine collection >300mg protein suggest significant proteinuria.
NICE does not make any specific recommendations for primary care. At present, usual practice would be to use a visually interpreted dipstick and to consider ≥1+ significant and warranting further assessment. 
Managing pre-eclampsia

Post-natal care and follow-up
All women should have a medical review at their post-natal check. If a woman needs ongoing antihypertensive treatment in the post-natal period, the following antihypertensives have no known adverse effects on babies receiving breast milk:
Avoid diuretics in women who are breast-feeding or expressing breast milk. There is insufficient evidence to comment on the safety of ARBs, amlodipine and other ACEI for breast-feeding mothers.
There is also an increased risk of the same problems in subsequent pregnancies.
Women with pre-eclampsia should aim for a BMI within the healthy range before their next pregnancy.
Risk of developing hypertension in later life?
It is well known that women who have hypertensive disorders in pregnancy (gestational hypertension, pre-eclampsia, eclampsia or HELLP syndrome) are at increased risk of developing hypertension later in life. A massive cohort study has now quantified the risks and looked at how quickly hypertension recurs (BMJ 2017:358:j3078) .
About one-third of women with hypertension in pregnancy developed hypertension in later life.
The hypertension may present as soon as 1y after delivery.
Another cohort study looked at women who had had hypertension in pregnancy, to identify what factors increased the risk of hypertension in later life (BMJ 2017; 358:j30240) .
The main risk identified was obesity: the researchers estimated that 25% of all cases of hypertension in later life were attributable to obesity, and that modifying lifestyle to reduce obesity would reduce the number of women who developed hypertension in later life. We make every effort to ensure the information in these articles is accurate and correct at the date of publication, but it is of necessity of a brief and general nature, and this should not replace your own good clinical judgement, or be regarded as a substitute for taking professional advice in appropriate circumstances. In particular check drug doses, side-effects and interactions with the British National Formulary. Save insofar as any such liability cannot be excluded at law, we do not accept any liability for loss of any type caused by reliance on the information in these articles.
2017;358:j3245).
Do you code hypertensive disorders in pregnancy? Do you ensure you monitor these women for hypertension? Do you do this ad hoc or do you want to be more proactive?
NICE on hypertension in pregnancy
Offer all women with 1 high risk or 2 moderate risk factors 75mg aspirin daily from 12w of gestation to reduce the risk of pre-eclampsia. Educate all pregnant women about the symptoms and signs of pre-eclampsia. Avoid prescribing ACEI and ARBs for women with chronic hypertension who are hoping to start a family. Gestational hypertension is BP >140/90 in the absence of proteinuria. All women with a BP >150/100 require same-day assessment in secondary care. Pre-eclampsia is hypertension and at least 1+ proteinuria. All women with BP >140/90 and proteinuria need same-day assessment in secondary care. Review anti-hypertensive medication in the post-natal period, and adjust to take account of breast-feeding. Remember women with gestational hypertension and pre-eclampsia are at increased risk of hypertension later in life.
Discuss these guidelines with your community midwife and PHCT. How will you identify women eligible for aspirin treatment? Do you have, or could you design, information for recognising the symptoms of pre-eclampsia, and to explain why a woman has been offered aspirin?
All our courses are:
Relevant Developed and presented by practising GPs and immediately relevant to clinical practice.
Challenging Stimulating and thought-provoking.
Unbiased Completely free from any pharmaceutical company sponsorship.
Fun!
Humorous and entertainingwithout compromising the content!
Are they for me?
Our courses are designed for:
• GPs, trainers and appraisers preparing for appraisal and revalidation or wanting to keep up to date across the whole field of general practice.
• GP ST1, 2 & 3, looking for the perfect launch pad into general practice and help with AKT and CSA revision.
• GPs who want to be brought up to speed following maternity leave or a career break.
• General Practice Nurses, especially those seeing patients with chronic diseases.
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What's not included?
Our courses contain NO theorists, NO gurus, NO sponsors, NO reps on the day! Just real-life GPs who will be back at the coal face as soon as the course has finished.
www.gp-update.co.uk
Our comprehensive one-day update courses for GPs, GP STs, and General Practice Nurses. We do all the legwork to bring you up to speed on the latest issues and guidance.
What's included?
• 6 CPD credits in a lecture-based format, with plenty of time for interaction, humour and video clips, to keep you focussed and awake.
• A printed copy of the relevant handbook including the results of the most important research in primary care over the last 5 years and covering the subjects more extensively than possible in the course.
The GP Update Course -our flagship course!
With the amount of evidence and literature inundating us, it can be hard to know which bits should change our practice, and how.
The GP Update Course is designed to be very relevant to clinical practice and help you meet the requirements for revalidation.
We collate and synthesise the evidence for you so you don't have to! Using a lecture based format, with plenty of time for interaction, the GP presenters discuss the results of the most important evidence and guidance, placing them in the context of what is already known about this topic. The presenters also concentrate on what it means to you and your patients in the consulting room tomorrow. 
London
Lead. Manage. Thrive! -The management skills course for GPs
If you've been waiting for a job as a leader to develop your leadership and management skills then you're missing out! Leadership starts with identifying and taking control over what is in your hands right now! Lead. Manage. Thrive! will give you the confidence to skilfully negotiate, deal with difficult conversations, influence colleagues and bosses, delegate and be proactive about managing your workload.
The course is for anyone who wants to step up, find a better way of working and gain a toolkit of strategies to become a successful and resilient practitioner! The MSK and Chronic Pain Update Course -New MSK problems are the most common reason for seeing a GP and represent 30% of repeat GP visits. We want to help build your confidence. On the course we will tackle:
The evidence-base for common MSK conditions including osteoarthritis, spondyloarthritis, polymyalgia, fibromyalgia and much more. Diagnosis: why waddling like a duck might help; and what to do when there is no diagnosis! Why chronic pain is 'in the brain' -and more importantly, what we and our patients can do about it.
We will provide you with a new narrative and a tool box of strategies you can take back to the surgery and start using the next day. Our Women's Health Update has ALL NEW CONTENT for 2018! This completely refreshed one day update will arm you with the skills to manage this area of general practice with confidence! Expect the latest on perimenopausal contraception, low libido, fertility, post-coital bleeding and the 'abnormal' cervix as well as benign breast disease and lots more! We promise it'll be interactive, fun and relevant for ALL GPs and GP STs!
London
The Cancer Update Course
Within the next 15 years the need for cancer care will double and you will look after as many cancer survivors as diabetics. Shared care follow up will become the norm, and secondary care will pass responsibility to us. A key 2015 Lancet Oncology commission paper warned that: "GPs are inadequately trained and resourced to manage the growing demand for cancer care in high income countries".
Education for GPs was one of their five key recommendations -we can help you get ahead of the curve! Established GPs and GP STs can use this course to bridge the gap in traditional GP cancer education which has focussed heavily on referral and end of life care missing out the whole journey in between.
This course is able to look in much more detail at the big picture behind the disease perhaps most feared by our patients and, let's face it, that 1 in 2 of us will be diagnosed with over our lifetime. 
London
GP Update Course:
GP £195 | GP Registrar £150 | Nurse £150
All other courses:
£225 or £210 for members of www.gpcpd.com (GPCPD members, please log in and then click on the relevant button within the 'Member information' box on the right of the home screen to get your discount code)
Join us for our first ever Update Roadshow event! Red Whale is heading to the beach and pitching up in Brighton for four full days to bring you our most popular courses all in one hit! Choose one, two, three or four Updates and return to your surgery refreshed and invigorated with the latest evidence, guidelines and practical advice on a vast range of topics -all relevant to your practice! All courses will be taking place at The Brighton Hilton Metropole. 
